Abstract
Bioassay-guided fractionation of Limonium myrianthum crude extract led the isolation of four known phenolic compounds including myricetin (1), myricitrin (2), gallic acid (3) and 6''-galloylmyricetin-3-O-β-D-glucopyranoside (4). Their structures were elucidated by spectroscopic analyses including HR-MS, 1D, and 2D NMR. The in vitro anti-leukemia activity of the phenolic compounds 1 – 4 against two human leukemia cell lines HL60 and K562 were evaluated after 48h exposure. The estimated IC 50 values (nM) found as 5.8, 23.6, 13.8, 38.0 for HL60 cells and 15.0, 25.0, 32.0, 48 for K562 cells for compound 1 – 4, respectively. There were no significant differences in the sensitivity of the above two cell lines to the four compounds. To our knowledge, this is the first time to evaluate their anti-leukemia against two human leukemia cell lines HL60 and K562. Fig. 1